Response rates to different therapies according to AIHA serological type
| Therapy (no. of patients) . | Warm IgG (n = 123) . | Warm IgG+C (n = 51) . | Cold (n = 64) . | Mixed (n = 24) . | Atypical (n = 15) . |
|---|---|---|---|---|---|
| Steroids (277) | CR 50%, PR 32% (n = 123) | CR 49%, PR 27% (n = 51) | CR 27%, PR 42% (n = 64) | CR 37.5%, PR 25% (n = 24) | CR 40%, PR 40% (n = 15) |
| Immunosuppressants (76) | CR 57%, PR 30% (n = 30) | CR 27%, PR 53% (n = 15) | CR 28%, PR 39% (n = 18) | CR 11%, PR 56% (n = 9) | CR 25%, PR 75% (n = 4) |
| Rituximab standard dose (55) | CR 45%, PR 19% (n = 11) | CR 43%, PR 50% (n = 14) | CR 45%, PR 35% (n = 20) | CR 50%, PR 33% (n = 6) | CR 0%, PR 100% (n = 1) |
| Rituximab LD (19) | CR 80%, PR 0% (n = 5) | CR 100%, PR 0% (n = 2) | CR 37.5%, PR 37.5% (n = 8) | CR 100%, PR 0% (n = 2) | CR 100%, PR 0% (n = 2) |
| Splenectomy (32) | CR 75%, PR 0% (n = 16) | CR 70%, PR 10% (n = 10) | CR 33%, PR 0% (n = 3) | CR 100%, PR 0% (n = 1) | CR 100%, PR 0% (n = 2) |
| Therapy (no. of patients) . | Warm IgG (n = 123) . | Warm IgG+C (n = 51) . | Cold (n = 64) . | Mixed (n = 24) . | Atypical (n = 15) . |
|---|---|---|---|---|---|
| Steroids (277) | CR 50%, PR 32% (n = 123) | CR 49%, PR 27% (n = 51) | CR 27%, PR 42% (n = 64) | CR 37.5%, PR 25% (n = 24) | CR 40%, PR 40% (n = 15) |
| Immunosuppressants (76) | CR 57%, PR 30% (n = 30) | CR 27%, PR 53% (n = 15) | CR 28%, PR 39% (n = 18) | CR 11%, PR 56% (n = 9) | CR 25%, PR 75% (n = 4) |
| Rituximab standard dose (55) | CR 45%, PR 19% (n = 11) | CR 43%, PR 50% (n = 14) | CR 45%, PR 35% (n = 20) | CR 50%, PR 33% (n = 6) | CR 0%, PR 100% (n = 1) |
| Rituximab LD (19) | CR 80%, PR 0% (n = 5) | CR 100%, PR 0% (n = 2) | CR 37.5%, PR 37.5% (n = 8) | CR 100%, PR 0% (n = 2) | CR 100%, PR 0% (n = 2) |
| Splenectomy (32) | CR 75%, PR 0% (n = 16) | CR 70%, PR 10% (n = 10) | CR 33%, PR 0% (n = 3) | CR 100%, PR 0% (n = 1) | CR 100%, PR 0% (n = 2) |
CR, Hb ≥12 g/dL; PR, Hb ≥10 g/dL. Rituximab at standard dose, 375 mg/m2 per week for 4 weeks; LD, fixed dose of 100 mg/wk for 4 weeks.